Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 77-89 http://medscipublisher.com/index.php/cge 88 Laliotis G., and Lin P., 2022, Abstract B032: Pancancer genomic analysis reveals histone H3K36 and H3K27 modifiers and readers as prognostic factors in patients with cancer, Cancer Research, 82(23_Supplement_2): B032. Laugesen A., Højfeldt J.W., and Helin K., 2019, Molecular mechanisms directing PRC2 recruitment and H3K27 methylation, Molecular Cell, 74(1): 8-18. https://doi.org/10.1016/j.molcel.2019.03.011 Li G., Tian Y., and Zhu W., 2020, The roles of histone deacetylases and their inhibitors in cancer therapy, Frontiers in Cell and Developmental Biology, 8: 576946. https://doi.org/10.3389/fcell.2020.576946 Li L., Carroll P., and Dahiya R., 2005, Epigenetic changes in prostate cancer: implication for diagnosis and treatment, Journal of the National Cancer Institute, 97(2): 103-115. https://doi.org/10.1093/JNCI/DJI010 Li Y., and Seto E., 2016, HDACs and HDAC inhibitors in cancer development and therapy, Cold Spring Harbor Perspectives in Medicine, 6(10): a026831. https://doi.org/10.1101/cshperspect.a026831 Marsh D.J., Ma Y., and Dickson K.A., 2020, Histone monoubiquitination in chromatin remodelling: focus on the histone H2B interactome and cancer, Cancers, 12(11): 3462. https://doi.org/10.3390/cancers12113462 Mason, 2024, High-throughput sequencing technology: a new chapter in epigenetics and disease research, Cancer Genetics and Epigenetics, 12(1): 47-54 https://doi.org/10.5376/cge.2024.12.0006 Neganova M.E., Klochkov S.G., Aleksandrova Y.R., and Aliev G., 2020, Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress, Seminars in Cancer Biology, 83: 452-471. https://doi.org/10.1016/j.semcancer.2020.07.015 Nowacka-Zawisza M., and Wiśnik E., 2017, DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review), Oncology Reports, 38(5): 2587-2596. https://doi.org/10.3892/or.2017.5972 Perry A., Watson R., Lawler M., and Hollywood D., 2010, The epigenome as a therapeutic target in prostate cancer, Nature Reviews Urology, 7: 668-680. https://doi.org/10.1038/nrurol.2010.185 Popovic R., Martínez-García E., Giannopoulou E., Zhang Q., Zhang Q., Ezponda T., Shah M., Zheng Y., Will C., Small E., Hua Y., Bulic M., Jiang Y., Carrara M., Calogero R., Kath W., Kelleher N., Wang J., Elemento O., and Licht J., 2014, Histone methyltransferase MMSET/NSD2 Alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation, PLoS Genetics, 10(9):e1004566. https://doi.org/10.1371/journal.pgen.1004566 Purnell B., 2021, Cross-talk between histone modifications, Science, 371: 358-360 https://doi.org/10.1126/SCIENCE.371.6527.358-L Ramaiah M.J., Tangutur A., and Manyam R., 2021, Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy, Life Sciences, 277: 119504 https://doi.org/10.1016/j.lfs.2021.119504 Schizas D., Mastoraki A., Naar L., Tsilimigras D., Katsaros I., Fragkiadaki V., Karachaliou G., Arkadopoulos N., Liakakos T., and Moris D., 2019, Histone deacetylases (HDACs) in gastric cancer: an update of their emerging prognostic and therapeutic role, Current Medicinal Chemistry, 27(36): 6099-6111. https://doi.org/10.2174/0929867326666190712160842 Schmitz M., Higgins J., and Seibert M., 2020, Priming chromatin for segregation: functional roles of mitotic histone modifications, Cell Cycle, 19: 625-641 https://doi.org/10.1080/15384101.2020.1719585 Seligson D., Horvath S., Shi T., Yu H., Tze S., Grunstein M., and Kurdistani S., 2005, Global histone modification patterns predict risk of prostate cancer recurrence, Nature, 435: 1262-1266. https://doi.org/10.1038/nature03672 Sigismondo G., Papageorgiou D.N., and Krijgsveld J., 2022, Cracking chromatin with proteomics: from chromatome to histone modifications, Proteomics, 22(15-16): 2100206. https://doi.org/10.1002/pmic.202100206 Slaughter M., Shanle E., Khan A., Chua K., Hong T., Boxer L., Allis C., Josefowicz S., Garcia B., Rothbart S., Strahl B., and Davis I., 2021, HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies, Cell Reports, 34(3): 108638. https://doi.org/10.1016/j.celrep.2020.108638 Sugiura M., Sato H., Kanesaka M., Imamura Y., Sakamoto S., Ichikawa T., and Kaneda A., 2020, Epigenetic modifications in prostate cancer, International Journal of Urology, 28(2):140-149. https://doi.org/10.1111/iju.14406 Szczepanek J., Skorupa M., Jarkiewicz-Tretyn J., Cybulski C., and Tretyn A., 2023, Harnessing epigenetics for breast cancer therapy: the role of dna methylation, histone modifications, and microRNA, International Journal of Molecular Sciences, 24(8): 7235. https://doi.org/10.3390/ijms24087235 Tian X., Zhang S., Liu H., Zhang Y., Blair C., Mercola D., Sassone-Corsi P., and Zi X., 2013, Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention, Current Cancer Drug Targets, 13(5): 558-579. https://doi.org/10.2174/1568009611313050007
RkJQdWJsaXNoZXIy MjQ4ODYzNA==